由一种抗HPV免疫瘤治疗的透视病毒载体诱导和重塑的T细胞免疫力
Ingrid Fert1, Laëtitia Douguet1, Benjamin Vesin1
1Pasteur-TheraVectys Joint Lab, Institut Pasteur, Université de Paris, Virology Department, 28 Rue du Dr. Roux, F-75015, Paris, France.
NPJ vaccines
|June 10, 2024
概括
这项研究表明,加强Lenti-HPV-07免疫疗法可以增强抗人类乳头瘤病毒 (HPV) T细胞免疫力,而不会影响疗效. T细胞反应与检查点抑制剂协同作用,为HPV诱导的癌症治疗提供了新的希望.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 病毒学 病毒学
背景情况:
- 人类乳头瘤病毒 (HPV) 基蛋白E6和E7驱动恶性瘤.
- 伦蒂-HPV-07是一种伦蒂病毒载体疗法,通过诱导CD8+T细胞反应来向HPV诱导的瘤.
- 了解T细胞动态和组合疗法对于优化Lenti-HPV-07疗效至关重要.
研究的目的:
- 为了研究抗载体免疫对Lenti-HPV-07同源增强的影响.
- 在Lenti-HPV-07 prime和boost之后纵向跟踪T细胞谱的演变.
- 评估Lenti-HPV-07诱导的T细胞与检查点抑制剂的协同潜力.
主要方法:
- 在周围血液细胞 (PBL) 和HPV特异性T细胞中对T细胞受体 (TCR) 变量β和α链mRNA进行深度测序.
- 长度监测T细胞克隆型扩张和多样化后的T细胞克隆型扩张和多样化.
- 评估T细胞效应因子功能与抗TIM3和抗NKG2A单克隆抗体的协同作用.
主要成果:
- 抗载体免疫不妨碍对Lenti-HPV-07的同源增强,以增强抗HPVT细胞免疫力.
- 在PBL中,T细胞克隆类型显示了prime后的超扩张和PBL后的多样化.
- 林蒂-HPV-07诱导的T细胞效应因子功能与抗TIM3和抗NKG2A疗法协同作用.
结论:
- 同源增强有效地放大了抗HPVT细胞免疫力,无论抗载体反应如何.
- 对T细胞谱系的分析显示,在 prime 和 boost 之后,有不同的动态.
- 伦蒂-HPV-07免疫疗法在结合检查点抑制剂治疗HPV媒介恶性瘤时显示出有前途.
相关概念视频
01:27Tumor Immunotherapy
514
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514
01:30Cancer Vaccines
354
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
354
01:29Immune Response Against Viral Pathogens
776
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
776
01:27Cytotoxic T Cells-mediated Immune Response
891
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
891
01:51Vaccinations
44.4K
Overview
44.4K